CBG shows promise for the treatment of MS

This study examined the in vitro and in vivo effects of CBG on multiple sclerosis (MS) markers and was published in the journal Biomolecules in February 2023.

The in vitro ("test tube") part of the study focused on measuring the effects of CBG molecules on microglial inflammation, which plays an important role in the development of MS through the release of cytokines and reactive oxygen species like nitric oxide. They also found that using CBG in conjunction with other compounds created an additive positive effect.

Their in vivo study involved using an accepted mice model of MS called experimental autoimmune encephalomyelitis (EAE). 

The in vitro results show that CBG has positive effects in reducing some markers that contribute to MS:

The highest concentration of CBG used attenuated cell viability by 70%

Cannabigerol attenuated the microglial production of nitric oxide in BV2 microglia and primary glial cells

concomitant treatment of the cells with cannabigerol and telmisartan (a neuroprotective angiotensin receptor blocker) decreased nitric oxide production additively

Inducible nitric oxide synthase (iNOS) expression was also reduced by cannabigerol

Moreover, tumor necrosis factor-α (TNF-α), a major cytokine involved in MS, was significantly reduced by cannabigerol in both cell cultures

The experiments with the mice model (in vivo) were also encouraging:

The clinical scores of EAE mice were attenuated upon cannabigerol treatment

lumbar sections of EAE mice showed enhanced neuronal loss (relative to control mice), which was restored by cannabigerol treatment.

Conclusions from the authors:

This study provides evidence that CBG by itself attenuated the neurological deficit score in EAE mice. 

the set of experiments presented in this work indicates that cannabigerol [CBG] possesses an appealing therapeutic potential for the treatment of MS

The full text article is here at Pubmed Central.